Document Detail


Coronary heart disease risk reduction in postmenopausal women: the role of statin therapy and hormone replacement therapy.
MedLine Citation:
PMID:  15249765     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The incidence of coronary heart disease in women rises sharply in the years following menopause, and prescribing of hormone replacement therapy in the belief that it might compensate for the loss of estrogen-mediated cardioprotection is widespread. However, controlled trials have failed to show a beneficial effect of hormone replacement therapy on the incidence of coronary events, and recent evidence suggests that hormone replacement therapy may even have a deleterious effect on primary coronary heart disease prevention. Statins are recommended as first-line treatment for lowering low-density lipoprotein cholesterol levels in women and are extremely valuable in reducing coronary heart disease risk in this group. An awareness of the benefits of appropriate statin treatment, and evidence showing that they can be safely added to hormone replacement therapy prescribed for the relief of menopausal symptoms and osteoporosis, provides the opportunity to optimize clinical outcomes for coronary heart disease among the large and expanding population of postmenopausal women.
Authors:
Michael Clearfield
Related Documents :
12629235 - Caffeine, postmenopausal estrogen, and risk of parkinson's disease.
2525895 - Prior x-ray therapy for acne related to tumors of the parotid gland.
11786685 - Medical problems of adult turner's syndrome.
12443835 - The role of treatment intentions and concerns about side effects in women's decision to...
16703205 - Rapid high-volume population screening for three major risk factors of future stroke: p...
8404115 - Chronic obstructive pulmonary disease early intervention trial (lung health study). bas...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Preventive cardiology     Volume:  7     ISSN:  1520-037X     ISO Abbreviation:  Prev Cardiol     Publication Date:  2004  
Date Detail:
Created Date:  2004-07-13     Completed Date:  2004-11-10     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9813731     Medline TA:  Prev Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  131-6     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of North Texas Health Science Center, Fort Worth 76107, USA. mclearfi@hsc.unt.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Coronary Artery Disease / epidemiology,  prevention & control*
Estrogen Replacement Therapy*
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Postmenopause
Prevalence
Risk Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Non-high-density lipoprotein cholesterol: an alternate target for lipid-lowering therapy.
Next Document:  Predictors of physical function in patients with peripherial arterial disease and claudication.